ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bristol-Myers HIV R&D Will Go To ViiV

by Michael McCoy
January 4, 2016 | APPEARED IN VOLUME 94, ISSUE 1

Bristol-Myers Squibb will sell its pipeline of investigational HIV medicines to ViiV Healthcare for $350 million plus potentially more than $2 billion in milestone payments. BMS, a pioneer in HIV drug discovery, says the deal is in keeping with its decision, announced in June 2015, to discontinue virology drug discovery. ViiV was formed in 2009 to combine the HIV drug businesses of GlaxoSmithKline and Pfizer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment